ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2016
Opportunities and obstacles to the development of nanopharmaceuticals for human use.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of nano formulation of natural products for the treatment of inflammatory bowel disease: drug delivery and pharmacological targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2018Pooled it
- Co-delivery of SN38 and rapamycin albumin bound nanoparticles against breast Cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- The efferocytosis process in aging: Supporting evidence, mechanisms, and therapeutic prospects for age-related diseases.Journal of advanced research · 2025Review
- Lipid-based nanoparticles: innovations in ocular drug delivery.Frontiers in molecular biosciences · 2024Review
- The role of artificial intelligence and data science in nanoparticles development: a review.Nanomedicine (London, England) · 2024Review
- Advanced Delivery System of Polyphenols for Effective Cancer Prevention and Therapy.Antioxidants (Basel, Switzerland) · 2023Review
- The combination of nanotechnology and traditional Chinese medicine (TCM) inspires the modernization of TCM: review on nanotechnology in TCM-based drug delivery systems.Drug delivery and translational research · 2022Review
- An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market.Journal of pharmaceutical innovation · 2022Review
- Nanopharmaceutics: Part II-Production Scales and Clinically Compliant Production Methods.Nanomaterials (Basel, Switzerland) · 2020Review
- The consolidation of nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.Scientific reports · 2018Article
- Uptake and transport of pullulan acetate nanoparticles in the BeWo b30 placental barrier cell model.International journal of nanomedicine · 2018Article
- Dendrimers for Ocular Drug Delivery.Canadian journal of chemistry · 2017Article
- Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.International journal of nanomedicine · 2017Review
- Erratum to: Opportunities and obstacles to the development of nanopharmaceuticals for human use.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2016Article
- Blockage of both the extrinsic and intrinsic pathways of diazinon-induced apoptosis in PaTu cells by magnesium oxide and selenium nanoparticles.International journal of nanomedicineArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical nanotechnology has generated breakthrough developments in improving health care and human life from its emergence. The biomaterials employed mainly aim at improving drug delivery systems, imaging and diagnostic technologies while the nanoscale materials are in widespread use in other industries such as electronics and optics. Such advancement may revolutionize the drug development and therapy with new and more efficient treatments. Although, nanotechnology assists humankind in improving its well being, it has certain limitations that entail thorough investigation by the regulatory and scientific authorities. To address concerns regarding the safety and toxicity profile of the nanopharmaceuticals, we have reviewed the challenges and solutions of nanopharmaceuticals use in human health and the related health risks. In this regard, regulatory and scientific bodies such as countries' Food and Drug Administration (FDA), Organization for Economic Co-operation and Development (OECD), European Medicine Agency (EMA), Environmental Protection Agency (EPA), National Institute for Occupational Safety and Health (NIOSH), and World Health Organization (WHO) can participate in developing and reinforcing safety measures and regulatory frameworks to insure the public health. The regulatory authorities may enforce the nanopharmaceutical industries to conduct comprehensive toxicity tests and monitor the adverse drug reaction reports in close collaboration with the scientific community to act accordingly and inform the public as the implementation of the strategy. Nanopharmaceuticals have tremendous potential for human use as therapeutic or diagnostic agents. But their toxicity profile should be well addressed and the respective regulatory framework developed and reinforced by the authorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.